OncoPlex Diagnostics, Culver City, MD
Sheeno P. Thyparambil , Jin You , Kang Liu , Hui Sun , Junjie Peng , Sanjun Cai , Yaqi Li , Pingping Bao , Qing Li , Yani Zhang , Zheng Li , Jingzhi Yang , Ziyu Yin , Xiaoming Yao , Xiurui Zhu , Shiying Hao , Robert Heaton , James Schilling , Karl G. Sylvester , Xuefeng B. Ling
Background: Implementation of population screening for colorectal cancer (CRC) before colonoscopy can reduce the challenge of the overall capacity of bowel examination and improve survival. Blood based CRC assessment biomarkers, on a triage concept, can lead to improved selection to colonoscopy and cost-effective CRC care. Methods: Innovative multi-omics approaches, with global and targeted LCMS data production (metabolomics, lipidomics, and 2D proteomics) and integrative data analytics, were applied to discover serological biomarkers to assess nonadvanced adenoma and identify stage I/II colorectal bowel lesions. A cohort of 2396 normal, 660 adenoma, 953 stage I, and 101 stage II blood samples, was constructed to discover screening biomarkers to support case finding of patients at high risk for nonadvanced adenoma and stage I/II cancer for subsequent diagnostic colonoscopy. Results: A three-analyte mProbe panel was constructed which outperformed the commercial assays of plasma methylated septin 9 and fecal Cologuard tests. Sensitivity: (1) nonadvanced adenoma–Cologuard 17.2%, mProbe 76.0%; (2) stage I-III-Cologuard 93.3%, stage I-II Septin 9 (ARUP laboratories) 77%, stage I-II mProbe: 92.3%. Specificity–Cologuard 89.8%, Septin 9 (ARUP laboratories) 88%, mProbe 90.7%. Conclusions: mProbe triage concept of a blood-based protein biomarker panel promises the precision to allow future CRC screening, and reduce the low-risk utilization of unnecessary, unpleasant and risk-associated bowel examinations.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Yoanna S. Pumpalova
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Zainab Aziz
2023 ASCO Annual Meeting
First Author: Ehsan Irajizad
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Derek W. Ebner